Tagged: culture

Why We Do Clinical Research: A Reminder

Sometimes in the rush of daily responsibilities, we lose sight of why we chose clinical development as our life’s work.  Last week a pleasant surprise provided a vivid reminder of why I focus on finding more efficient ways to run clinical programs and studies.  The unexpected reminder came from The Triangle Business Journal, the leading… Read more »

Risk in Outsourcing: The Three Horsemen of the (Potential) Apocalypse

As the CEO of a CRO, I’m frequently asked about the role of risk in outsourced drug development. There’s no definite answer to this, but as we develop strong, long-term relationships with our partners, I suggest there are three ways of looking at this issue. First, every sponsor faces the risk of launching a drug… Read more »

The Rhetoric of “Risk Sharing”

Derek Lowe’s observation about AstraZeneca’s bracing for change also applies to the pharma industry as a whole: “…things can’t go on the way that they have been.” AstraZeneca is not alone in failing to get enough new drugs approved to sustain their business model, but they’ve made themselves the poster child for that dilemma. Somehow… Read more »

Clinical Development Relay: The Hurdles We Face

Now that I’ve had the chance to settle in to the blogosphere, I’d like to tell you a little more about what I hope to accomplish with “Trials Without Tribulations.” It is obvious to me (and others in the industry, see here, here, and here) that biopharma faces a number of sizable challenges. Tribulations, if… Read more »

Breaking with Bad Culture: Trading Risk-Aversion for Efficiency

A recent article in Nature Reviews Drug Discovery by Jack Scannell and his colleagues at Sanford Bernstein identifies four primary causes of declining pharma R&D productivity, including the “throw money at it” tendency. Scannell and co-authors list the increasing number and scale of clinical trials as secondary symptoms. David Shaywitz provides an excellent recap, and… Read more »